In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Sequenom SQNM with a Buy rating, but lowered the price target from $7.50 to $6.00.
In the report, Jefferies noted, “SQNM's flagship MaterniT21 test continues to ramp at a blistering clip, formal reimbursement contracts are building, and its ability to capture payment for tests accessioned is clearly escalating. Our revised target ($6 from $7.50) reflects a more conservative realized ASP expectation for T21 and assumes SQNM captures 45% of the high-risk mkt by 2016. Assuming coverage at Buy.”
Sequenom closed on Thursday at $4.11.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.